Accredo wins Flolan agreement

Topline results from a phase 3 trial showed 64.1% of patients on atogepant achieved a 50% or greater reduction in mean monthly migraine days during months 4 to 6.

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

Investigators also found that a change in brain functional network connectivity could also be associated with type 2 diabetes risk.

In this episode, Natalie DiPietro Mager, PharmD, PhD speaks with David Bright, PharmD, MBA, professor at Ferris State University College of Pharmacy.

PP405 targets the primary biological pathway that controls the natural hair growth cycle, separating it from existing therapies.

Researchers conducted a review that provided updated evidence regarding the pneumococcal disease burden, the evolution of pneumococcal vaccines, and the latest immunization strategies.